Fluorometholone

Corticosteroid — CARDIOVASCULAR SYSTEM

Key facts

Fluorometholone is an ofp drug in the Corticosteroid class catalogued in DrugCentral. It was first approved by the FDA in 1972. Its mechanism of action is classified as Corticosteroid Hormone Receptor Agonists. DrugCentral lists 3 molecular targets, including NR3C1, PGR and Ar. Recorded indications include Allergic conjunctivitis, Corneal abrasion, Corneal ulcer and Cyclitis.

• Approval status: ofp (first approved 1972 by the FDA).
• Drug class: Corticosteroid.
• Mechanism of action: Corticosteroid Hormone Receptor Agonists.
• Molecular targets: NR3C1, PGR and Ar (3 listed in DrugCentral).
• Indications: Allergic conjunctivitis, Corneal abrasion, Corneal ulcer, Cyclitis and Herpes zoster keratitis and others.
• ATC code: C05AA06 (Corticosteroids).
• Molecular formula: C22H29FO4; molecular weight 376.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (11)

• Allergic conjunctivitis
• Corneal abrasion
• Corneal ulcer
• Cyclitis
• Herpes zoster keratitis
• Iridocyclitis
• Iritis
• Post-Op Ocular Inflammation
• Punctate keratopathy
• Rosacea
• Uveitis

Off-label uses (4)

• Allergic otitis externa
• Otitis externa
• Otitis Externa Eczema
• Otitis Externa Seborrhea

Contraindications (16)

• Anemia due to enzyme deficiency
• Bacterial infection of eye
• Deficiency of glucose-6-phosphate dehydrogenase
• Diabetes mellitus
• Eye infection
• Fungal infection of eye
• Herpes simplex dendritic keratitis
• Herpes simplex keratitis
• Krukenberg spindle
• Ocular hypertension
• Open-angle glaucoma
• Porphyria
• Severe myopia
• Tuberculosis of eye
• Vaccinia keratitis
• Viral eye infection

Mechanism & targets

• Mechanism of action (MoA): Corticosteroid Hormone Receptor Agonists
• Established pharmacologic class: Corticosteroid

Molecular targets (3)

Target	Gene	Action	Activity
Glucocorticoid receptor	NR3C1	agonist	Ki 8.80
Progesterone receptor	PGR	unknown	Ki 6.97
Androgen receptor	Ar	unknown	Ki 6.07

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1972-01-12	FDA	—	ALLERGAN

ATC classification

ATC code	Therapeutic hierarchy
C05AA06	CARDIOVASCULAR SYSTEM › VASOPROTECTIVES › AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE › Corticosteroids
D07AB06	DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, PLAIN › Corticosteroids, moderately potent (group II)
D07CB03	DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS › Corticosteroids, moderately potent, combinations with antibiotics
D07XB04	DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, OTHER COMBINATIONS › Corticosteroids, moderately potent, other combinations
D10AA01	DERMATOLOGICALS › ANTI-ACNE PREPARATIONS › ANTI-ACNE PREPARATIONS FOR TOPICAL USE › Corticosteroids, combinations for treatment of acne
S01BA07	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS › Corticosteroids, plain
S01BB03	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS › Corticosteroids and mydriatics in combination
S01CA07	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION › Corticosteroids and antiinfectives in combination
S01CB05	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION › Corticosteroids/antiinfectives/mydriatics in combination

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Grip strength	225.2
Autoimmune disorder	142.5
Bone erosion	133.7
Porphyria acute	129.2
Adjustment disorder with depressed mood	122.2
Dislocation of vertebra	121.6
Swollen joint count	121.6
Exostosis	112.5
Breast cancer stage III	109.2
Foot deformity	108.4
Ear infection	101.0
Colitis ulcerative	100.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Fluorometholone is on its molecule page.

• Molecular formula: C₂₂H₂₉FO₄
• Molecular weight: 376.47 g/mol
• CAS number: 426-13-1
• InChIKey: FAOZLTXFLGPHNG-KNAQIMQKSA-N
• PubChem CID: 9878

C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Fluorometholone used for?

DrugCentral lists the following indications for Fluorometholone: Allergic conjunctivitis, Corneal abrasion, Corneal ulcer, Cyclitis, Herpes zoster keratitis, Iridocyclitis, Iritis and Post-Op Ocular Inflammation and others.

How does Fluorometholone work?

Fluorometholone is classified as Corticosteroid Hormone Receptor Agonists; its molecular targets in DrugCentral include NR3C1 (agonist), PGR and Ar.

When was Fluorometholone first approved?

Fluorometholone was first approved by the FDA in 1972.

What drug class does Fluorometholone belong to?

Fluorometholone is in the Corticosteroid class.

What is the chemical formula of Fluorometholone?

Fluorometholone has the molecular formula C22H29FO4 and a molecular weight of 376.47 g/mol.

Sources

• DrugCentral drug card 1208 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200600 — compound record and bioactivity
• PubChem CID 9878 — chemical identifiers
• DrugBank DB00324 — drug record
• FDA UNII SV0CSG527L — substance identity
• DailyMed: FDA labels for Fluorometholone — current prescribing information (label search)
• UniProt P04150 (NR3C1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.